^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TPBG expression

    i
    Other names: TPBG, Trophoblast Glycoprotein, 5T4, 5T4 Oncofetal Trophoblast Glycoprotein, Wnt-Activated Inhibitory Factor, 5T4 Oncotrophoblast Glycoprotein, 5T4 Oncofetal Antigen, WAIF1, M6P1, 5T4-AG, 5T4AG
    Entrez ID:
    7162
    Related biomarkers:
    Expression
    1m
    Targeting the Tumour Antigen 5T4 using CAR-T Cells for the Treatment of Acute Myeloid Leukaemia. (PubMed, Mol Cancer Ther)
    A murine model for AML demonstrated that CAR-T cells recognise and kill in vivo 5T4-expressing tumour cells. These results highlight 5T4 as a promising target for immune intervention in AML and that CAR-T cells can be considered a powerful personalised therapeutic approach to treat AML.
    Journal • CAR T-Cell Therapy • IO biomarker
    |
    NPM1 (Nucleophosmin 1) • TPBG (Trophoblast Glycoprotein)
    |
    NPM1 mutation • TPBG expression
    1m
    Preclinical evaluation and pilot clinical study of [68Ga]Ga-NOTA-H006 for non-invasive PET imaging of 5T4 oncofetal antigen. (PubMed, Eur J Nucl Med Mol Imaging)
    [68Ga]Ga-NOTA-H006, which can visualize 5T4 expression in vivo, has been successfully developed. This opens up opportunities for non-invasively studying 5T4 expression through nuclear medicine. Further clinical investigations are warranted to explore its clinical value in disease progression and companion diagnosis.
    Preclinical • Journal
    |
    TPBG (Trophoblast Glycoprotein)
    |
    TPBG expression • TPBG positive
    9ms
    Study of ASN004 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Kirilys Therapeutics Inc. | Recruiting --> Active, not recruiting | N=45 --> 19 | Trial completion date: Mar 2027 --> Sep 2024 | Trial primary completion date: Mar 2026 --> Jun 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    TPBG (Trophoblast Glycoprotein)
    |
    TPBG expression
    |
    ASN004
    11ms
    PET Imaging of 68Ga-NOTA-H006 in Malignancy (clinicaltrials.gov)
    P=N/A, N=15, Not yet recruiting, YiHui Guan
    New trial
    |
    TPBG (Trophoblast Glycoprotein)
    |
    TPBG expression
    1year
    Study of ASN004 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=45, Recruiting, Kirilys Therapeutics Inc. | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    TPBG (Trophoblast Glycoprotein)
    |
    TPBG expression
    |
    ASN004
    over1year
    Preclinical characterization of CBA-1535, a novel bi-specific tribody, with two binding sites to 5T4 and one site to CD3ε (AACR 2023)
    These results provide the strong rationale for further clinical evaluation ofCBA-1535 in 5T4 positive tumors. CBA-1535 is now under the phase 1 trial in Japan (jRCT2031210708), with 2 parts, the monotherapy and the combination with Pembrolizumab.
    Preclinical • PD(L)-1 Biomarker • IO biomarker
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha) • TPBG (Trophoblast Glycoprotein) • CD69 (CD69 Molecule) • IL2 (Interleukin 2) • AIF1 (Allograft Inflammatory Factor 1)
    |
    TPBG expression • TPBG positive
    |
    Keytruda (pembrolizumab) • CBA-1535
    over1year
    Immunohistochemical Detection of 5T4 in Renal Cell Carcinoma. (PubMed, Appl Immunohistochem Mol Morphol)
    These data identify mAbs suitable for detecting 5T4 in formalin-fixed, paraffin-embedded tissues and demonstrate both interpatient and histologic subtype heterogeneity. Our validated 5T4 IHC protocol will facilitate biomarker studies and support the therapeutic targeting of 5T4.
    Journal • IO biomarker
    |
    TPBG (Trophoblast Glycoprotein)
    |
    TPBG expression
    2years
    5T4-CD40 bispecific antibodies activate immune responses in a 5T4-dependent manner (SITC 2022)
    Conclusions We have generated bispecific antibodies specific to both CD40 and 5T4 that could achieve APC activation only in 5T4-expressing tumor microenvironment and demonstrate anti-tumor efficacy without inducing systemic toxicity. The preclinical data warrant further development of 5T4 x CD40 bispecific antibody as a potential therapeutic option for solid tumor.
    IO biomarker
    |
    CD8 (cluster of differentiation 8) • TPBG (Trophoblast Glycoprotein) • CD40 (CD40 Molecule) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)
    |
    TPBG expression
    over2years
    OXB-302: 5T4-Targeting CAR-T Cells Are Cytotoxic Against Low-Expressing Cells and Successfully Eliminate Leukaemic Stem Cells In Vitro (ASGCT 2022)
    Together, these data evidence the fact that 5T4-targeted CAR-T cells show specificity and efficient of cell killing. This suggests that OXB-302 could successfully kill 5T4-expressing leukaemic blasts from AML patients and further eliminate 5T4-expressing leukaemic stems cells, which would help to prevent relapse.
    Preclinical • CAR T-Cell Therapy • IO biomarker
    |
    CD38 (CD38 Molecule) • TPBG (Trophoblast Glycoprotein) • CD34 (CD34 molecule)
    |
    TPBG expression
    |
    OXB302